SAB Biotherapeutics Ownership | Who Owns SAB Biotherapeutics?

SAB Biotherapeutics Ownership Summary

SAB Biotherapeutics is owned by 35.93% institutional investors, 0.84% insiders, and 63.23% retail investors. Vivo capital is the largest institutional shareholder, holding 59.13% of SABS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.80% of its assets in SAB Biotherapeutics shares.

SABS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	SAB Biotherapeutics	35.93%	0.84%	63.23%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vivo capital	11.42M	59.13%	$43.74M
Caligan partners lp	7.97M	41.26%	$30.51M
Perceptive advisors	6.43M	33.30%	$24.63M
Commodore capital lp	4.40M	22.79%	$16.86M
Ra capital management	4.40M	22.79%	$16.86M
Balyasny asset management	3.76M	19.47%	$14.40M
Adage capital partners gp	3.41M	17.63%	$13.04M
Vanguard group	1.85M	17.33%	$6.91M
Millennium management	3.03M	15.70%	$11.62M
Woodline partners lp	2.85M	14.77%	$10.92M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Vivo capital	11.42M	3.65%	$43.74M
Propel bio management	1.01M	2.45%	$3.89M
Caligan partners lp	7.97M	2.03%	$30.51M
Monashee investment management	500.00K	1.04%	$1.92M
Commodore capital lp	4.40M	0.98%	$16.86M
Perceptive advisors	6.43M	0.48%	$24.63M
Stempoint capital lp	375.00K	0.28%	$1.44M
Sphera funds management	566.39K	0.24%	$1.14M
Fifth lane capital, lp	46.50K	0.22%	$178.09K
Ra capital management	4.40M	0.18%	$16.86M

Top Buyers

Holder	Shares	% Assets	Change
Caligan partners lp	7.97M	2.03%	7.97M
Perceptive advisors	6.43M	0.48%	5.63M
Adage capital partners gp	3.41M	0.02%	3.41M
Balyasny asset management	3.76M	0.02%	3.29M
Millennium management	3.03M	0.00%	2.71M

Top Sellers

Holder	Shares	% Assets	Change
Blackstone	860.17K	0.01%	-1.28M
Renaissance	-	-	-80.84K
Verition fund management	-	-	-26.87K
Simplify asset management	187.23K	0.01%	-21.00K
Silver oak securities	-	-	-20.19K

New Positions

Holder	Shares	% Assets	Change	Value
Caligan partners lp	7.97M	2.03%	7.97M	$30.51M
Adage capital partners gp	3.41M	0.02%	3.41M	$13.04M
Boothbay fund management	1.48M	0.07%	1.48M	$5.67M
Ensign peak advisors	1.38M	0.01%	1.38M	$5.27M
Soleus capital management	1.05M	0.16%	1.05M	$4.02M

Sold Out

Holder	Change
Raymond james financial	-45.00
Sbi securities	-50.00
Sachetta	-4.10K
Caxton	-10.53K
Creative planning	-11.85K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	28	-41.67%	6,938,021	-80.91%	35	0.03%	20	-37.50%	3	-25.00%
Dec 31, 2025	30	-11.76%	18,100,153	-35.41%	169	0.19%	18	-18.18%	4	100.00%
Sep 30, 2025	34	36.00%	28,023,938	1356.64%	301	70.37%	22	144.44%	2	-50.00%
Jun 30, 2025	25	-3.85%	1,923,784	-12.93%	20	3.66%	9	-18.18%	4	-33.33%
Mar 31, 2025	26	4.00%	2,209,552	-15.93%	23	2.95%	11	22.22%	6	-14.29%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.12M	2.80%	-
Vanguard Institutional Extnd Mkt Idx Tr	304.89K	0.40%	-
Simplify Propel Opportunities ETF	187.23K	0.27%	-
Fidelity Extended Market Index	136.67K	0.19%	89.37K
A4Investments SICAV SIF ACCI IlanaA2EURH	75.00K	0.10%	-
Blackrock Extended Mkt Fund CF	72.87K	0.10%	-
Spartan Extended Market Index Pool E	8.36K	0.09%	356.00
Extended Equity Market Fund K	62.04K	0.09%	57.53K
BlackRock Extended Equity Market Fund K	62.04K	0.08%	57.53K
Vanguard Instl Ttl Stck Mkt Idx Tr	52.85K	0.08%	21.00K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 07, 2023	Sullivan Eddie Joe	Chief Executive Officer	Buy	$1.53K
Nov 30, 2023	King Michael	CHIEF FINANCIAL OFFICER	Buy	$4.50K
Nov 29, 2023	Reich Samuel J	Executive Chairman	Buy	$9.84K
Sep 13, 2022	HAMILTON CHRISTINE E		Buy	$7.30K
Sep 07, 2022	Sullivan Eddie Joe	CHIEF EXECUTIVE OFFICER	Buy	$10.32K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-
2025 Q1	-	-
2024 Q4	-	-

SABS Ownership FAQ

Who Owns SAB Biotherapeutics?

SAB Biotherapeutics shareholders are primarily institutional investors at 35.93%, followed by 0.84% insiders and 63.23% retail investors. The average institutional ownership in SAB Biotherapeutics's industry, Biotech Stocks , is 35.75%, which SAB Biotherapeutics exceeds.

Who owns the most shares of SAB Biotherapeutics?

SAB Biotherapeutics’s largest shareholders are Vivo capital (11.42M shares, 59.13%), Caligan partners lp (7.97M shares, 41.26%), and Perceptive advisors (6.43M shares, 33.30%). Together, they hold 133.70% of SAB Biotherapeutics’s total shares outstanding.

Does Blackrock own SAB Biotherapeutics?

BlackRock is not among the top 10 institutional shareholders of SAB Biotherapeutics.

Who is SAB Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Vivo capital is SAB Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 3.65% of its assets in 11.42M SAB Biotherapeutics shares, valued at 43.74M$.

Who is the top mutual fund holder of SAB Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of SAB Biotherapeutics shares, with 2.80% of its total shares outstanding invested in 2.12M SAB Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools